DRG Market Assessment reports
Access comprehensive market intelligence covering Disease Landscape & Forecast, Epidemiology Intelligence, Biosimilars Intelligence, China In-depth and more.
Gastrointestinal Stromal Tumor, Malignant Melanoma, Renal Cell Carcinoma | Access and Reimbursement | EU5 | 2016
The success of an anticancer therapy is not only dependent on the outcome of its pivotal trial, but also on that trial’s design, which is examined by the regulatory bodies, payers, and…
Breast Cancer, Non-Small-Cell Lung Cancer, Ovarian Cancer | Access and Reimbursement | Realizing the Potential of Personalized Medicine in Oncology | US | 2016
Biomarker-driven prescribing plays an increasingly prominent role in key oncology indications. The choice of therapy for breast cancer has long been informed by the presence of key biomarkers, and…
Glioblastoma, Prostate cancer, Squamous Cell Carcinoma of the Head and Neck | Access and Reimbursement | US | 2016
The success of an anticancer therapy is not only dependent on the outcome of its pivotal trial, but also on that trial’s design, which is examined by the regulatory bodies, payers, and…
Breast Cancer, Colorectal Cancer, Non-Small-Cell Lung Cancer | Access and Reimbursement | Biomarkers in Oncology | China | 2016
Introduction Oncology is increasingly moving toward a personalized treatment approach, enlisting predictive biomarkers to guide therapy choice. This trend is already being felt in indications as…
Prostate Cancer (U.S. Physician and Payer Perspectives on Novel Treatment Options for Prostate Cancer) | Physician & Payer Forum | US | 2015
The U.S. Physician and Payer Perspectives on Novel Treatment Options for Prostate Cancer report surveyed 50 medical oncologists, 52 urologists, and 30 MCO pharmacy and medical directors to capture…
Biosimilars Advisory Service : Physician Perspectives on Granulocyte Colony-Stimulating Factors and Monoclonal Antibodies in Oncology | US | 2015
In recent years, biosimilars of epoetin alfa and filgrastim have been approved and launched in major markets. Uptake of these products among oncologists is increasing, driven by payers and…
U.S. Clinician and Payer Receptivity to Immune Checkpoint Inhibitors in Oncology | Physician & Payer Forum | US | 2015
Ushering in a New Era of Cancer Immunotherapies in NSCLC, Malignant Melanoma, Renal Cell Carcinoma, and SCCHN The field of cancer immunotherapy has witnessed considerable advances over the past few…
